Monte Rosa Therapeutics, Inc.
GLUE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001826457
In the last 90 days, Monte Rosa Therapeutics, Inc. insiders filed 0 open-market purchases and 3 sales; 192 institutions reported holding it in 13F filings for Q2 2026, worth $2.24B in total; Duquesne Family Office is the only superinvestor holding it.
Q4 2022 vs. Q3 2022
How the institutions holding Monte Rosa Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 70 | 66 | −4 |
| Shares | 40.3M | 41.2M | +979.2K (+2.4%) |
| Value | $328.8M | $313.8M | −$15.0M (−4.6%) |
New holders (6)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Renaissance Technologies LLC | 16,400 | $125.0K | 0.00% |
| Alliancebernstein L.P. | 12,400 | $94.4K | 0.00% |
| SG Americas Securities, LLC | 10,632 | $81.0K | 0.00% |
| Principal Financial Group Inc | 10,374 | $78.9K | 0.00% |
| UBS Group AG | 9,247 | $70.4K | 0.00% |
| CWM, LLC | 34 | $0 | 0.00% |
Sold out (10)
Institutions that held Monte Rosa Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| UBS Oconnor LLC | 91,615 | $748.0K |
| HRT Financial LP | 85,798 | $700.0K |
| Jane Street Group, LLC | 50,222 | $410.0K |
| Squarepoint Ops LLC | 28,410 | $232.0K |
| Gsa Capital Partners LLP | 19,084 | $156.0K |
| Balyasny Asset Management LLC | 19,031 | $155.0K |
| Susquehanna International Group, LLP | 18,916 | $155.0K |
| Jump Financial, LLC | 18,200 | $149.0K |
| Invesco Ltd. | 10,003 | $81.0K |
| Wells Fargo & Company | 80 | $1.00K |